{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=0.005%25+Latanoprost+dosed+once.",
    "query": {
      "intervention": "0.005% Latanoprost dosed once."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T11:35:49.493Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00716859",
      "title": "A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Timolol",
          "type": "DRUG"
        },
        {
          "name": "latanoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "36 Weeks",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "36 Weeks to 18 Years"
      },
      "enrollment_count": 139,
      "start_date": "2008-07",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2021-02-03",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 7,
      "location_summary": "Pembroke Pines, Florida • Atlanta, Georgia • Indianapolis, Indiana + 3 more",
      "locations": [
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00716859"
    },
    {
      "nct_id": "NCT00811564",
      "title": "An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2008-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2011-09-21",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Slingerlands, New York",
      "locations": [
        {
          "city": "Slingerlands",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00811564"
    },
    {
      "nct_id": "NCT04445519",
      "title": "Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "NCX 470 0.065% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "NCX 470 0.1% (initial phase of trial)",
          "type": "DRUG"
        },
        {
          "name": "NCX 470 0.1% (remainder of trial)",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% (remainder of trial)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 691,
      "start_date": "2020-06-01",
      "completion_date": "2022-09-16",
      "has_results": true,
      "last_update_posted_date": "2025-06-24",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Newport Beach, California",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04445519"
    },
    {
      "nct_id": "NCT01426464",
      "title": "Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Latanoprost Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "0.005% Latanoprost dosed once.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nanduri, Padma, M.D., FACS",
      "sponsor_class": "INDIV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2011-09",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2011-08-31",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Visalia, California",
      "locations": [
        {
          "city": "Visalia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01426464"
    },
    {
      "nct_id": "NCT00759941",
      "title": "A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Glaucoma"
      ],
      "interventions": [
        {
          "name": "Brinzolamide 1% ophthalmic solution (Azopt)",
          "type": "DRUG"
        },
        {
          "name": "Placebo eye drops",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005% ophthalmic solution (Xalatan)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "35 Years and older"
      },
      "enrollment_count": 86,
      "start_date": "2007-10",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Fort Worth, Texas",
      "locations": [
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00759941"
    },
    {
      "nct_id": "NCT00572455",
      "title": "Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "PF-04217329 - Lowest Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-04217329 - Low Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-04217329 - Middle Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-04217329 - High Middle Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-04217329 - High Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-4217329 - Highest Dose",
          "type": "DRUG"
        },
        {
          "name": "PF-04217329 - Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost Vehicle",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 318,
      "start_date": "2007-12-11",
      "completion_date": "2009-06-26",
      "has_results": true,
      "last_update_posted_date": "2021-04-30",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 23,
      "location_summary": "Artesia, California • Newport Beach, California • Petaluma, California + 17 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Poway",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00572455"
    },
    {
      "nct_id": "NCT03657797",
      "title": "Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma, Open-Angle",
        "Hypertension, Ocular"
      ],
      "interventions": [
        {
          "name": "NCX 470",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 656,
      "start_date": "2018-08-01",
      "completion_date": "2019-08-23",
      "has_results": true,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657797"
    },
    {
      "nct_id": "NCT04630808",
      "title": "MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "NCX 470 0.1%",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost 0.005%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nicox Ophthalmics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 696,
      "start_date": "2020-11-09",
      "completion_date": "2025-06-25",
      "has_results": false,
      "last_update_posted_date": "2025-09-08",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 63,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 54 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04630808"
    },
    {
      "nct_id": "NCT03216902",
      "title": "A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Open-angle Glaucoma, Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical ultra-low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical low dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical medium dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Topical high dose of DE-126 Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "0.005% Latanoprost Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Santen Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2017-07-25",
      "completion_date": "2018-02-27",
      "has_results": true,
      "last_update_posted_date": "2020-10-23",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 12,
      "location_summary": "Artesia, California • Mission Hills, California • Newport Beach, California + 9 more",
      "locations": [
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Mission Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Petaluma",
          "state": "California"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03216902"
    },
    {
      "nct_id": "NCT01896180",
      "title": "Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension",
        "Elevated Intraocular Pressure"
      ],
      "interventions": [
        {
          "name": "ALZ-1101",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alleanza Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2013-07",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2014-09-30",
      "last_synced_at": "2026-10-05T11:35:49.493Z",
      "location_count": 1,
      "location_summary": "Morrow, Georgia",
      "locations": [
        {
          "city": "Morrow",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01896180"
    }
  ]
}